Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$17.40 USD
-0.07 (-0.40%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $17.40 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
A Value D Growth B Momentum C VGM
Balance Sheet
Fiscal Year End for Integra LifeSciences Holdings Corporation falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 309 | 457 | 513 | 470 | 199 |
Receivables | 259 | 263 | 232 | 226 | 275 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 390 | 325 | 317 | 310 | 316 |
Other Current Assets | 100 | 117 | 91 | 231 | 68 |
Total Current Assets | 1,058 | 1,162 | 1,154 | 1,237 | 858 |
Net Property & Equipment | 340 | 311 | 312 | 288 | 337 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 46 | 46 | 57 | 74 | 13 |
Intangibles | 2,123 | 2,165 | 2,159 | 1,922 | 1,986 |
Deposits & Other Assets | 58 | 57 | 16 | 11 | 15 |
Total Assets | 3,782 | 3,890 | 3,782 | 3,615 | 3,303 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 15 | 38 | 45 | 34 | 45 |
Accounts Payable | 92 | 102 | 62 | 55 | 113 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 113 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 176 | 159 | 213 | 170 | 156 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 9 | 7 | 5 | 17 | 5 |
Total Current Liabilities | 307 | 321 | 340 | 401 | 331 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 35 | 63 | 46 | 16 | 37 |
Convertible Debt | 570 | 567 | 564 | 475 | 105 |
Long-Term Debt | 915 | 838 | 937 | 933 | 1,199 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 200 | 139 | 120 | 187 | 118 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2,194 | 2,085 | 2,098 | 2,100 | 1,887 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 1,302 | 1,277 | 1,265 | 1,291 | 1,214 |
Retained Earnings | 947 | 879 | 699 | 532 | 399 |
Other Equity | -15 | 10 | -45 | -74 | -76 |
Treasury Stock | 647 | 363 | 234 | 235 | 120 |
Total Shareholder's Equity | 1,588 | 1,804 | 1,685 | 1,515 | 1,417 |
Total Liabilities & Shareholder's Equity | 3,782 | 3,890 | 3,782 | 3,615 | 3,303 |
Total Common Equity | 1,588 | 1,804 | 1,685 | 1,515 | 1,417 |
Shares Outstanding | 78.10 | 83.60 | 84.70 | 84.20 | 85.80 |
Book Value Per Share | 20.33 | 21.58 | 19.89 | 17.99 | 16.51 |
Fiscal Year End for Integra LifeSciences Holdings Corporation falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 297 | 663 | 309 | 274 | 309 |
Receivables | 271 | 241 | 259 | 256 | 259 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 422 | 403 | 390 | 366 | 354 |
Other Current Assets | 122 | 108 | 100 | 131 | 129 |
Total Current Assets | 1,112 | 1,416 | 1,058 | 1,027 | 1,051 |
Net Property & Equipment | 374 | 345 | 340 | 319 | 318 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 46 | 34 | 46 | 56 | 56 |
Intangibles | 2,325 | 2,063 | 2,123 | 2,103 | 2,137 |
Deposits & Other Assets | 71 | 68 | 58 | 78 | 67 |
Total Assets | 4,075 | 4,078 | 3,782 | 3,739 | 3,778 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 24 | 19 | 15 | 10 | 5 |
Accounts Payable | 107 | 94 | 92 | 94 | 100 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 76 | 91 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 172 | 164 | 176 | 154 | 159 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 10 | 8 | 9 | 8 | 8 |
Total Current Liabilities | 328 | 302 | 307 | 356 | 378 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 87 | 31 | 35 | 74 | 71 |
Convertible Debt | 572 | 571 | 570 | 570 | 569 |
Long-Term Debt | 1,229 | 1,266 | 915 | 850 | 765 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 155 | 200 | 142 | 153 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2,540 | 2,480 | 2,194 | 2,160 | 2,094 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 1,302 | 1,311 | 1,302 | 1,262 | 1,284 |
Retained Earnings | 931 | 944 | 947 | 927 | 908 |
Other Equity | -19 | -11 | -15 | 2 | 5 |
Treasury Stock | 681 | 646 | 647 | 613 | 514 |
Total Shareholder's Equity | 1,534 | 1,598 | 1,588 | 1,579 | 1,683 |
Total Liabilities & Shareholder's Equity | 4,075 | 4,078 | 3,782 | 3,739 | 3,778 |
Total Common Equity | 1,534 | 1,598 | 1,588 | 1,579 | 1,683 |
Shares Outstanding | 77.50 | 78.60 | 78.10 | 78.10 | 81.40 |
Book Value Per Share | 19.80 | 20.33 | 20.33 | 20.22 | 20.68 |